SCHEMBL18085886

SCHEMBL18085886

CC(C)c1ccc(CN(CCF)CC23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 6/20 0.56
▸ HDAC1 Q13547 3/20 0.56
▸ HDAC3 O15379 2/20 0.56
▸ HDAC5 Q9UQL6 2/20 0.56
▸ P2RX7 Q99572 3/20 0.48
▸ CNR2 P34972 1/20 0.41
▸ CXCR3 P49682 2/20 0.40
▸ HDAC4 P56524 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ EPHX2 P34913 1/20 0.34
▸ PYCR1 P32322 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18088400 0.85 HDAC6 (0.60) HDAC6HDAC1HDAC3HDAC5P2RX7
SCHEMBL18085887 0.80 P2RX7 (0.74) HDAC6HDAC1HDAC3HDAC5P2RX7
SCHEMBL19678424 0.73 HDAC6 (0.85) HDAC6HDAC1HDAC3HDAC5P2RX7
SCHEMBL17483887 0.72 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC5HDAC4
SCHEMBL25793264 0.71 P2RX7 (0.46) HDAC6HDAC1HDAC3HDAC5P2RX7
SCHEMBL23259079 0.68 P2RX7 (0.49) HDAC6HDAC1HDAC3HDAC5P2RX7
SCHEMBL20004363 0.68 PYCR1 (0.57) CNR2PYCR1
SCHEMBL18085885 0.67 HDAC6 (0.57) HDAC6HDAC1HDAC3P2RX7HDAC2
SCHEMBL18085908 0.66 HDAC6 (0.60) HDAC6HDAC1HDAC3HDAC5P2RX7
SCHEMBL12015809 0.63 HRH3 (0.61) HDAC6CNR2HDAC8PYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10842891-B2 Imaging histone deacetylases with a radiotracer using positron emission tomography THE GENERAL HOSPITAL CORPORATION (US) 2020-11-24 — — US disclosed
US-20190240357-A1 IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY THE GENERAL HOSPITAL CORPORATION 2019-08-08 — — US disclosed
US-20160271276-A1 IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY THE GENERAL HOSPITAL CORPORATION 2016-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240357-A1 IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY HDAC1, HDAC11, HDAC3 HDAC6 13/4885HDAC1 1/4885HDAC3 3/4885
US-20160271276-A1 IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY HDAC1, HDAC11, HDAC3 HDAC6 13/4885HDAC1 1/4885HDAC3 3/4885
US-10842891-B2 Imaging histone deacetylases with a radiotracer using positron emission tomography HDAC1, HDAC11, HDAC3 HDAC6 13/4885HDAC1 1/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback